Site search
2811 results for '' found
A randomized, open-label Phase III study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to phy
A randomized, open-label Phase III study in patients with previously treated unresectable or metastatic NRAS mutant cutaneous melanoma comparing the combination of naporafenib + trametinib to phy
/
A randomised, double-blind, placebo-controlled trial of erythropoietin alfa versus placebo in machnically ventilated critically ill patients following traumatic injury. (ACTRN12619001632189)
A randomised, double-blind, placebo-controlled trial of erythropoietin alfa versus placebo in machnically ventilated critically ill patients following traumatic injury. (ACTRN12619001632189)
/
A prospective study to assess the safety of a sub-scalp monitoring device for the recording of brain electrical activity associated with the occurrence of epileptic seizures (ACTRN12619001587190)
A prospective study to assess the safety of a sub-scalp monitoring device for the recording of brain electrical activity associated with the occurrence of epileptic seizures (ACTRN12619001587190)
/
A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation with Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR T-Cell Therapy for Large B-C
A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation with Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR T-Cell Therapy for Large B-C
/
Effect of cannabidiol on sleep in developmental and epileptic encephalopathies (ACTRN12623000855628p)
Effect of cannabidiol on sleep in developmental and epileptic encephalopathies (ACTRN12623000855628p)
/
An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer (ACTRN
An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer (ACTRN
/
ABT-CIP-10487 ENVISION Trial - Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients (NCT05932615)
ABT-CIP-10487 ENVISION Trial - Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients (NCT05932615)
/
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer’s Disease (NCT05
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer’s Disease (NCT05
/
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician’s Choice of Venetoclax in Combination with Azacitidine or
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician’s Choice of Venetoclax in Combination with Azacitidine or
/
Left Atrial Posterior Wall Isolation VS Left Atrial Posterior Wall isolation and Superior Vena Cava Isolation and Cavo-tricuspid isthmus Isolation and Mitral Isthmus Isolation for Recurrent Atria
Left Atrial Posterior Wall Isolation VS Left Atrial Posterior Wall isolation and Superior Vena Cava Isolation and Cavo-tricuspid isthmus Isolation and Mitral Isthmus Isolation for Recurrent Atria
/